05APR2024

CURRICULUM VITAE
Shigeyuki MATSUI, Ph.D.
Professor, Department of Biostatistics,
Nagoya University Graduate School of Medicine
65 Tsurumai-cho, Chuo-ku, Nagoya, Japan
Tel/Fax: +81-52-744-2487/2489
E-mail: smatsui(at)med.nagoya-u.ac.jp
Education:
Bachelor of Engineering, Dept. of Transportation Engineering, Tokyo Univ. of Sci., 1991
Master of Engineering, Dept. of Civil Engineering, Tokyo Univ. of Sci., 1993
Degree:Doctor of Engineering, Tokyo Univ. of Sci., 1999, Title of the Thesis: Design and analysisof randomized clinical trials with recurrent events.
Employment:
1993.4-1995.3, Biostatistician, Rhone-Poulenc Rorer, Inc.
1998.4-2001.3, Research Associate, Department of Health Sciences, Oita University of
Nursing and Health Sciences
2001.4-2002.4, Assistant Professor, Department of Health Sciences, Oita University of
Nursing and Health Sciences
2002.5-2008.6, Associate Professor, Department of Pharmacoepidemiology, Kyoto
University School of Public Health2008.7-2009.9, Associate Professor, Department of Data Science, The Institute of Statistical
Mathematics
2009.10-2013.3, Professor, Department of Data Science, The Institute of Statistical
Mathematics
2013.4-present, Professor, Department of Biostatistics, Nagoya University Graduate Schoolof Medicine
Membership of Academic Societies:
International Biometric Society, American Statistical Association, Japan Statistical Society,
The Biometric Society of Japan, Japanese Society of Applied Statistics, Japanese Society of
Public Health

05APR2024

Professional Services:
Visiting Researcher, Translational Research Informatics Center, Foundation for Biomedical
Research and Innovation (2002-present)
The International Biometric Society, Representative Council Member (2011-2014),
Nominating Committee (2013-2014)
Current Drug Safety Editorial Board (2005-present)
Japanese Journal of Clinical Oncology Review Board (2005-present)
Annals of Oncology Review Board (2015-present)
Japanese Journal of Biometrics, Editor-in-chief (2009-2016)
Japanese Journal of Statistics and Data Science, Coordinating Editor (2018-2019)
The Biometric Society of Japan, Director (2007-2018), President (2019-2020)
Books:
1. Matsui S, Buyse M, Simon R (Editors). Design and Analysis of Clinical Trials for Predictive
Medicine. CRC Press, 2015.
2. Matsui S, Crowley J (Editors). Frontiers of Biostatistical Methods and Applications in ClinicalOncology, Springer, 2017.
3. Hirakawa A, Sato H, Daimon T, Matsui S. Modern Dose-Finding Designs for Cancer Phase I
Trials: Drug Combination and Molecularly Targeted Agents. Springer, 2018
4. Emura T, Chen YH, Matsui S, Rondeau V. Survival Analysis with Correlated Endpoints: Joint
Frailty-Copula Models, Springer, 2019.
5. Daimon T, Hirakawa A, Matsui S. Dose-Finding Designs for Early-Phase Cancer Clinical Trials:
A Brief Guidebook to Theory and Practice, Springer, 2019.
Book Chapters:
1. Matsui S. (2006). Statistical applications using DNA microarrays for cancer diagnosis andprognosis, Handbook of Statistics in Clinical Oncology, 2nd edn. (eds J.J. Crowley and D.P.
Ankerst), CRC Press, Boca Raton.
2. Matsui S, Noma H. (2012). Analysis of DNA microarrays, Handbook of Statistics in ClinicalOncology, 3rd edn. (eds JJ. Crowley and A Hoering), CRC Press, Boca Raton.
3. Noma H, Matsui S. (2012). Bayesian Ranking and Selection Methods in Microarray Studies,
Statistical Diagnostics for Cancer. (eds M. Dehmer and F. Emmert-Streib), Wiley.
4. Matsui S, Nonaka T, Choai Y. (2014). Design of phase III clinical trials with predictive biomarkers
for personalized medicine. In Developments in Statistical Evaluation of Clinical Trials (eds K.
van Montfort, J. Oud, W. Ghidey), Springer.

05APR2024

5. Hirakawa A, Matsui S. (2014). Dose-finding for two-agent combination phase I trials. In
Developments in Statistical Evaluation of Clinical Trials (eds K. van Montfort, J. Oud, W. Ghidey),
Springer.
6. Simon R, Matsui S, Buyse M. (2015). Clinical trials for predictive medicine: new paradigms andchallenges. In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S. Matsui, M.
Buyse, R. Simon), CRC Press.
7. Daimon T, Hirakawa A, Matsui S. (2015). Phase I dose-finding designs and their applicability totargeted therapies. In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S.
Matsui, M. Buyse, R. Simon), CRC Press.
8. Matsui S, Choai Y, Nonaka T. (2015). Phase III all-comers clinical trials with a predictive
biomarker. In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S. Matsui, M.
Buyse, R. Simon), CRC Press.
9. Matsui S. (2015). Statistical issues in clinical development and validation of genomic signatures.
In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S. Matsui, M. Buyse, R.
Simon), CRC Press.
10. Noma H, Matsui S. (2015). Univariate analysis for gene screening: beyond the multiple testing.
In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S. Matsui, M. Buyse, R.
Simon), CRC Press.
11. Matsui S. (2015). Development and validation of continuous genomic signatures in randomized
clinical trials. In Design and Analysis of Clinical Trials for Predictive Medicine. (eds. S. Matsui,
M. Buyse, R. Simon), CRC Press.
12. Matsui S. (2017). Phase III clinical trial designs incorporating predictive biomarkers: an overview.
In Frontiers of Biostatistical Methods and Applications in Clinical Oncology. (eds. S. Matsui, J.
Crowley), Springer.
13. Matsui S, Igeta M, Toyoizumi K. (2019). Biomarker-based phase II and III clinical trials in
oncology. In Textbook of Clinical Trials in Oncology. (eds. S. Halabi and S. Michiels), CRC Press.
Research Papers
Methodologies in Biostatistics:
1. Matsui S, Ohashi Y. (1999). Analysis of recurrent events: Application to a clinical trial of colony
stimulating factor with the endpoint of febrile neutropenia. Statistics in Medicine, 18, 2409-2420.
2. Matsui S, Miyagishi H. (1999). Design of clinical trials for recurrent events with periodic
monitoring. Statistics in Medicine, 18, 3005-3020.
3. Matsui S. (2004). Analysis of times to repeated events in two-arm randomized trials with
noncompliance and early withdrawal. Biometrics, 60, 965-976.
4. Matsui S. (2005). Sample size calculations for comparative clinical trials with over-dispersed

05APR2024

Poisson process data. Statistics in Medicine, 24, 1339-1356.
5. Matsui S. (2005). Stratified analysis in randomized trials with noncompliance. Biometrics, 61,
816-823.
6. Matsui S. (2006). Reducing false positive findings in statistical analysis of pharmacogenomic
biomarker studies using high-throughput technologies. Current Drug Safety, 1, 135-141.
7. Matsui S. (2006). Predicting survival outcomes using subsets of significant genes in prognostic
marker studies with microarrays. BMC Bioinformatics, 7, 156.
8. Matsui S, Ito M, Nishiyama H, Uno H, Kotani H, Watanabe J, Guilford P, Reeve A, Fukushima
M, Ogawa O. (2007). Genomic characterization of multiple clinical phenotypes of cancer using
multivariate linear regression models. Bioinformatics, 23, 732-738.
9. Matsui S, Zeng S, Yamanaka T, Shaughnessy J. (2008). Sample size calculations based on ranking
and selection in microarray experiments. Biometrics, 64, 217-226.
10. Matsui S, Yamanaka T, Barlogie B, Shaughnessy J, Crowley J. (2008). Clustering of significant
genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.
Statistics in Medicine, 27, 1106-1120.
11. Matsui S, Oura T. (2009). Sample sizes for a robust ranking and selection of genes in microarrayexperiments. Statistics in Medicine, 28, 2801-2816.
12. Oura T, Matsui S, Kawakami K. (2009). Sample size calculations for controlling the distributionof false discovery proportion in microarray experiments. Biostatistics, 10, 694-705.
13. Noma H, Matsui S, Omori T, Sato T. (2010). Bayesian ranking and selection methods using
hierarchical mixture models in microarray studies. Biostatistics, 11, 281-289.
14. Noma H, Matsui S. (2010). Optimality of gene ranking based on univariate P-values for detecting
differentially expressed genes. Japanese Journal of Biometrics, 31, 13-21.
15. Matsui S, Noma H. (2011). Estimation and selection in high-dimensional genomic studies fordeveloping molecular diagnostics. Biostatistics, 12, 223-233.
16. Matsui S, Noma H. (2011). Estimating effect sizes of differentially expressed genes for power andsample size assessments in microarray experiments. Biometrics, 67, 1225-1235.
17. Noma H, Matsui S. (2012). The optimal discovery procedure in multiple significance testing: anempirical Bayes approach. Statistics in Medicine, 31, 165-176.
18. Matsui S, Simon R, Qu P, Shaughnessy J, Barlogie B, Crowley J. (2012). Developing andvalidating continuous genomic signatures in randomized clinical trials for predictive medicine.
Clinical Cancer Research, 18, 6065-6073.
19. Noma H, Matsui S. (2013). Empirical Bayes ranking and selection methods via semiparametrichierarchical mixture models in microarray studies. Statistics in Medicine, 32, 1904-1916.
20. Mori K, Oura T, Noma H, Matsui S. (2013). Cancer outlier analysis based on mixture modelingof gene expression data. Computational and Mathematical Methods in Medicine, Article ID:

05APR2024

693901.
21. Noma H, Matsui S. (2013). An empirical Bayes optimal discovery procedure based on
semiparametric hierarchical mixture models. Computational and Mathematical Methods in
Medicine, Article ID: 568480.
22. Matsui S. (2013). Genomic biomarkers for personalized medicine: development and validation inclinical studies. Computational and Mathematical Methods in Medicine, Article ID: 865980.
23. Hirakawa A, Hamada C, Matsui S. (2013). A dose-finding approach based on shrunken predictive
probability for combinations of two agents in phase I trials. Statistics in Medicine, 32, 4515-4525.
24. Matsui S, Choai Y, Nonaka T. (2014). Comparison of statistical analysis plans in randomize-allphase III trials with a predictive biomarker. Clinical Cancer Research 20, 2820-2830.
25. Hirakawa A, Matsui S. (2014). Response to Letter to the Editor by Drs Wages et al. Statistics in
Medicine, 33, 12.
26. Hirakawa A, Wages NA, Sato H, Matsui S. (2015). A comparative study of adaptive dose-finding
designs for phase I oncology trials of combination therapies. Statistics in Medicine 34, 3194-3213.
27. Hirakawa A, Matsui S. (2015). Operating characteristics of restrictions on skipping dose level for
adaptive dose-finding method in two-agent phase I trials. Japanese Journal of Biometrics, 36, 112.
28. Choai Y, Matsui S. (2015). Estimation of treatment effects in all-comers randomized clinical trials
with a predictive marker. Biometrics 71, 25-32.
29. Noma H, Tanaka S, Matsui S, Cipriani A, Furukawa TA. (2017). Quantifying indirect evidence innetwork meta-analysis. Statistics in Medicine 36, 917-927.
30. Sugasawa S, Noma H, Otani T, Nishino J, Matsui S. (2017). An efficient and flexible test for rarevariant effects. European Journal of Human Genetics 25, 752-757.
31. Toyoizumi K, Matsui S. (2017). Correcting estimation bias in randomized clinical trials with atest of treatment-by-biomarker interaction. Statistics in Biopharmaceutical Research 9, 172-179.
32. Matsui S, Crowley J. (2018). Biomarker-stratified phase III clinical trials: enhancement with asubgroup-focused sequential design. Clinical Cancer Research 24, 994-1001.
33. Matsui S, Noma H, Qu P, Yoshio Sakai, Matsui K, Heuck C, Crowley J. (2018). Multi-subgroupgene screening using semi-parametric hierarchical mixture models and the optimal discovery
procedure: application to a randomized clinical trial in multiple myeloma. Biometrics 74, 313320.
34. Emura T, Nakatochi M, Matsui S, Michimae H, Rondeau V. (2018). Personalized dynamic
prediction of death according to tumour progression and high-dimensional genetic factors: Metaanalysis with a joint model. Statistical Methods in Medical Research 27, 2842-2858.
35. Otani T, Noma H, Nishino J, Matsui S. (2018). Re-assessment of multiple testing strategies formore efficient genome-wide association studies. European Journal of Human Genetics 26, 1038-

05APR2024

1048.
36. Shimamura F, Hamada C, Matsui S, Hirakawa A. (2018). Two-stage approach based on zone anddose findings for two-agent combination phase I/II trials. Journal of Biopharmaceutical Statistics
8:1-13.
37. Igeta M, Takahashi K, Matsui S. (2018). Power and sample size calculation incorporating
misspecifications of the variance function in comparative clinical trials with over-dispersed countdata. Biometrics 74, 1459-1467.
38. Nishino J, Ochi H, Kochi Y, Tsunoda T, Matsui S. (2018). Sample size for successful genomewide association study of major depressive disorder. Frontiers in Genetics 9: 227.
39. Nishino J, Kochi Y, Shigemizu D, Kato M, Ikari K, Ochi H, Noma H, Matsui K, Morizono T,
Boroevich K, Tsunoda T, Matsui S. (2018). Empirical Bayes estimation of semi-parametrichierarchical mixture models for unbiased characterization of polygenic disease architectures.
Frontiers in Genetics 9: 115.
40. Otani T, Noma H, Sugasawa S, Kuchiba A, Goto A, Yamaji T, Kochi Y, Iwasaki M, Matsui S,
Tsunoda T. (2019). Exploring predictive biomarkers from clinical genome-wide association
studies via multidimensional hierarchical mixture models. European Journal of Human Genetics
27, 140-149.
41. Emura T, Matsui S, Chen HY. (2019). compound.Cox: univariate feature selection and compound
covariate for predicting survival. Computer Methods and Programs in Biomedicine 168, 21-37.
42. Nonaka T, Igeta M, Matsui S. (2019). Statistical testing strategies for assessing treatment efficacy
and marker accuracy in phase III trials. Pharmaceutical Statistics 18, 459-475.
43. Kawabata T, Emoto R, Nishino J, Takahashi K, Matsui S. (2019). Two-stage analysis for selecting
fixed numbers of features in omics association studies. Statistics in Medicine 20; 38, 2956-2971.
44. Emoto R, Kawaguchi A, Takahashi K, Matsui S. (2020). Effect-size estimation using
semiparametric hierarchical mixture models in disease-association studies with neuroimaging
data. Computational and Mathematical Methods in Medicine. Article ID 7482403.
45. Morisawa J, Otani T, Nishino J, Emoto R, Takahashi K, Matsui S. (2021). Semi-parametricempirical Bayes factor for genome-wide association studies. European Journal of Human
Genetics 29, 800-807.
46. Igeta M, Matsui S. (2021). Blinded sample size re-estimation in comparative clinical trials withoverdispersed count data: Incorporation of misspecification of the variance function. Statistics inBiopharmaceutical Research 13, 170-180.
47. Emura T, Michimae H, Matsui S. (2022). Dynamic risk prediction via a joint frailty-copula modeland IPD meta-analysis: Building web applications. Entropy 24(5): 589.
48. Igeta M, Matsui S. (2022). Blinded sample size re-estimation for comparing over-dispersed countdata incorporating follow-up lengths. Statistics in Medicine 41, 5622-5644.

05APR2024

49. Toyoizumi K, Matsui S. (2022). Bias correction based on weighted likelihood for conditional
estimation of subgroup effects in randomized clinical trials. Statistics in Medicine 41, 5276-5289.
Practice of Biostatistics:
50. Shinohara M, Toyokuni S, Morimoto T, Matsui S, Honjo T, Shinohara T. (2003). Functional
assessment of self-renewal activity of male germline stem cells following cytotoxic damage andserial transplantation. Biology of Reproduction, 68, 1801-1807.
51. Matsui S, Sadaike T, Hamada C, Fukushima M. (2005). Creutzfeldt-Jakob disease and cadaveric
dura mater grafts in Japan: an updated analysis of incubation time. Neuroepidemiology, 24, 2225.
52. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. (2005). Prognostic factor
analysis for plaque psoriasis. Dermatology, 211, 103-106.
53. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T,
Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. (2005). Erythropoietin
as a retinal angiogenic factor in proliferative diabetic retinopathy. New England Journal of
Medicine, 353, 782-792.
54. Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. (2005). Erythropoietin as aretinal angiogenic factor. New England Journal of Medicine, 353, 2190-2191; author reply 21902191.
55. Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M. (2006). Lessons fromgefitinib-induced interstitial lung disease in Japan and proposal for the prevention of serious druginduced suffering: Problems in approval, pharmacovigilance, and regulatory decision-making
procedures. Pharmacy Practice, 4, 168-178.
56. Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, Ogawa O. (2007). P21activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resectionof bladder cancer. Journal of Urology, 178, 1073-1079.
57. Tada H, Matsui S, Kawahara M, Hosoe S, Hamada C, Fukushima M. (2008). Efficacy, toxicity
and cost analysis for non-platinum triplet (gemcitabine and vinorelbine followed by docetaxel) vs.
platinum-based chemotherapy in IIIB/IV non-small cell lung cancer: Single institution experience.
European Journal of Cancer Care, 17, 120-126.
58. Tsubouchi M, Morishita R, Tabata Y, Matsui S, Kawakami K. (2008). Critical issues for effective
collaboration between academia and industry in the field of regenerative medicine in Japan.
Regenerative Medicine, 3, 497-504.
59. Tsubouchi M, Matsui S, Banno Y, Kurokawa K, Kawakami K. (2008). Overview of the clinicalapplication of regenerative medicine products in Japan. Health Policy, 88, 62-72.
60. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T,

05APR2024

Matsuzawa Y. (2008). Long-term probucol treatment prevents secondary cardiovascular events: acohort study of patients with heterozygous familial hypercholesterolemia in Japan. Journal of
Atherosclerosis Thrombosis, 15, 292-303.
61. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK,
Konishi I. (2010). Identification of an ovarian clear cell carcinoma gene signature that reflects
inherent disease biology and the carcinogenic processes. Oncogene, 29, 1741-1752.
62. Yoshimura K, Kamoto T, Ogawa O, Matsui S, Tsuchiya N, Tada H, Murata K, Yoshimura K,
Habuchi T, Fukushima M. (2010). Medical mushrooms used for biochemical failure after radical
treatment for prostate cancer: An open-label study. International Journal of Urology, 17, 548-554.
63. Matsumura N, Mandai M, Okamoto T, Yamaguchi K, Yamamura S, Oura T, Baba T, Hamanishi J,
Kang HS, Matsui S, Mori S, Murphy SK, Konishi I. (2010). Sorafenib efficacy in ovarian clear
cell carcinoma revealed by transcriptome profiling. Cancer Science, 101, 2658-2663.
64. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, Mizokami Y, Chiba T, Matsui S,
Kanto T, Shimada K, Uchiyama S, Uemura N, Hiramatsu N. for the Lansoprazole Ulcer
Prevention Study Group (Low-Dose Aspirin Therapy). (2011). Lansoprazole for secondary
prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy:
Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-control
trial. Journal of Gastoroenterogy, 46, 724-735.
65. Shoji S, Suzuki M, Tomono Y, Bockbrader HN, Matsui S. (2011). Population pharmacokinetics
of pregabalin in healthy subjects and patients with postherpetic neuralgia or diabetic peripheral
neuropathy. British Journal of Clinical Pharmacology, 72, 63-76.
66. Sugano K, Kontani T, Katsuo S, Takei Y, Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S,
Kanto T, Soen S, Takeuchi T, Hiraishi H, Hiramatsu N. (2012). Lansoprazole for secondary
prevention of gastric or duodenal ulcers associated with long-term non-steroidal antiinflammatory drug (NSAID) therapy: Results of a prospective, multicenter, double-blind,randomized, double-dummy, active-controlled trial. Journal of Gastroenterology, 47, 540-552.
67. Negoro H, Kanematsu A, Doi M, Suadicani SO, Matsuo M, Imamura M, Okinami T, Nishikawa
N, Oura T, Matsui S, Seo K, Tainaka M, Urabe S, Kiyokage E, Todo T, Okamura H, Tabata Y,
Ogawa O. (2012). Involvement of urinary bladder Connexin43 and the circadian clock incoordination of diurnal micturition rhythm. Nature Communications, 3: 809.
68. Ishiguro M, Mochizuki H, Tomita N, Shimada Y, Takahashi K, Kotake K, Watanabe M, Kanemitsu
Y, Ueno H, Ishikawa T, Uetake H, Matsui S, Teramukai S, Sugihara K. (2012). Study protocol of
the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant
chemotherapy for stage II colon cancer. BMC Cancer, 12:281.
69. Sakaki N, Ashida K, Mizokami Y, Asaka M, Matsui S, Kanto T, Hiraishi H, Hiramatsu N, Sugano
K. (2012). Endoscopic evaluation of non-steroidal anti-inflammatory drug (NSAID)-induced

05APR2024

gastric and duodenal ulcers during prophylaxis with lansoprazole. Journal of Gastroenterology
and Hepatology Research, 1, 260-265.
70. Kokubo T, Matsui S, Ishiguro M. (2013). Meta-analysis of oro-cecal transit time in fasting subjects.
Pharmaceutical Research, 30, 402-411.
71. Atagi S, Katakami N, Yoshioka H, Fukuoka M, Kudoh S, Ogiwara A, Imai M, Ueda M, Matsui S.
(2013). Nested case control study of proteomic biomarkers for interstitial lung disease in Japanesepatients with non-small-cell lung cancer treated with erlotinib: a multicenter phase 4 study(JO21661). Clinical Lung Cancer, 14, 407-417.
72. Tsuchiya N, Matsui S, Narita S, Kamba T, Mitsuzuka K, Hatakeyama S, Horikawa Y, Inoue T,
Saito S, Ohyama C, Arai Y, Ogawa O, Habuchi T. (2013). Distinct cancer-specific survival inmetastatic prostate cancer patients classified by a panel of single nucleotide polymorphisms ofcancer-associated genes. Genes & Cancer, 4, 54-60.
73. Nakashima T, Sato H, Gyo K, Hato N, Yoshida T, Shimono M, Teranishi M, Sone M, Fukunaga
Y, Kobashi G, Takahashi K, Matsui S, Ogawa K. (2014). Idiopathic sudden sensorineural hearing
loss in Japan. Acta Oto-Laryngologica, 134, 1158-1163.
74. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka
S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M,
Fukunaga M. (2014). Fracture risk reduction with denosumab in Japanese postmenopausal womenand men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial(DIRECT). J Clin Endocrinol Metab., 99, 2599-2607.
75. Yanagida K, Iwase T, Yamamoto K, Ra E, Kaneko H, Murotani K, Matsui S, Terasaki H. (2015).
Sex-related differences in ocular blood flow of healthy subjects using laser speckle flowgraphy.
Invest Ophthalmol Vis Sci. 56, 4880-4890.
76. Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Fukunaga
M, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Okubo N,
Shiraki M, Nakamura T. (2015). Three-year denosumab treatment in postmenopausal Japanesewomen and men with osteoporosis: results from a 1-year open-label extension of the Denosumab
Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Osteoporos Int., 26, 765774.
77. Takanari K, Araki Y, Okamoto S, Sato H, Yagi S, Toriyama K, Yokotyama K, Murotani K, Matsui
S, Wakabayashi T, Kamei Y. (2015). Operative wound related complications after cranial
revascularization surgeries. J Neurosurgery 123; 1145-1150.
78. Iwase T, Yamamoto K, Ra E, Murotani K, Matsui S, Terasaki H. (2015). Diurnal variations inblood flow at optic nerve head and choroid in healthy eyes: diurnal variations in blood flow.
Medicine, 94, e519.
79. Ishikawa T, Uetake H, Murotani K, Kobunai T, Ishiguro M, Matsui S, Sugihara K. (2016).

05APR2024

Genome-wide DNA copy-number analysis in ACTS-CC trial of adjuvant chemotherapy for stage
III colonic cancer. Anticancer Res., 36, 853-860.
80. Kobayashi M, Iwase T, Yamamoto K, Ra E, Murotani K, Matsui S, Terasaki H. (2016).
Association between photoreceptor regeneration and visual acuity following surgery for
rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci., 57, 889-898.
81. Takagishi M, Sawada M, Ohata S, Asai N, Enomoto A, Takahashi K, Weng L, Ushida K, Ara H,
Matsui S, Kaibuchi K, Sawamoto K, Takahashi M (2017). Daple coordinates planar polarized
microtubule dynamics in ependymal cells and contributes to hydrocephalus. Cell Reports 20, 960972.
82. Nishikimi M, Matsuda N, Matsui K, Takahashi K, Ejima T, Liu K, Ogura T, Higashi M, Umino
H, Makishi G, Numaguchi A, Matsushima S, Tokuyama H, Nakamura M, Matsui S. (2016).
CAST: a new score for early prediction of neurological outcomes after cardiac arrest before
therapeutic hypothermia with high accuracy. Intensive Care Med. 42, 2106-2107.
83. Sayo A, Ueno S, Kominami T, Nishida K, Inooka D, Nakanishi A, Yasuda S, Okado S, Takahashi
K, Matsui S, Terasaki H. (2017). Longitudinal study of visual field changes determined by
Humphrey Field Analyzer 10-2 in patients with Retinitis Pigmentosa. Scientific Reports 7, 16383.
84. Nishikimi M, Matsuda N, Matsui K, Takahashi K, Ejima T, Liu K, Ogura T, Higashi M, Umino
H, Makishi G, Numaguchi A, Matsushima S, Tokuyama H, Nakamura M, Matsui S. (2017). A
novel scoring system for predicting the neurologic prognosis prior to the initiation of induced
hypothermia in cases of post-cardiac arrest syndrome: the CAST score. Scandinavian Journal ofTrauma, Resuscitation, and Emergency Medicine 25, 49.
85. Okumura J, Shindo Y, Takahashi K, Sano M, Sugino Y, Ichikawa M, Ogasawara T, Shindoh J,
Nomura F, Yagi T, Yamamoto M, Taniguchi H, Suzuki R, Saka H, Matsui S, Hasegawa Y. (2018).
Implication of β-lactam plus macrolide combination therapy on mortality in patients with
community-onset pneumonia at low risk for drug-resistant pathogens. Respirology 23, 526-534.
86. Horisaki K, Takahashi K, Ito H, Matsui S. (2018). A dose-response meta-analysis to coffee
consumption and colorectal cancer risk in the Japanese population: Application of a cubic-spline
model. Journal of Epidemiology 28, 503-509.
87. Funahashi S, Okazaki Y, Nishiyama T, Ohyoshi H, Yasui H, Nishida K, Matsui S, Toyokuni S.
(2018). Global overexpression of divalent metal transporter 1 delays crocidolite-induced
mesothelial carcinogenesis in male mice. Free Radical Research 12, 1-10.
88. Nishikimi M, Numaguchi A, Takahashi K, Matsui S, Matsuda N. (2018). The authors reply.
Critical Care Medicine 46, e1010-e1011.
89. Nishikimi M, Numaguchi A, Takahashi K, Matsui S, Matsuda N. (2018). The authors reply.
Critical Care Medicine 46, e1225-e1226.
90. Ogura T, Nakamura Y, Takahashi K, Nishida K, Kobashi D, Matsui S. (2018). Treatment of

05APR2024

patients with sepsis in a closed intensive care unit is associated with improved survival: anationwide observational study in Japan. Journal of Intensive Care 6, 57.
91. Nishikimi M, Ogura T, Matsui K, Takahashi K, Fukaya K, Liu K, Morita H, Nakamura M, Matsui
S, Matsuda N. (2018). Accuracy of the first interpretation of early brain CT images for predicting
the prognosis of post-cardiac arrest syndrome patients at the emergency department. Journal of
Intensive Care 6, 26.
92. Komura T, Yano M, Miyake A, Takabatake H, Miyazawa M, Ogawa N, Seki A, Honda M, Wada
T, Matsui S, Kaneko S, Sakai Y. (2018). Immune condition of colorectal cancer patients featured
by serum chemokines and gene expressions of CD4+ cells in blood. Canadian Journal of
Gastroenterology and Hepatology 7436205.
93. Hayashi K, Oshima H, Shimizu M, Kobayashi K, Matsui S, Nishida Y, Usui A. (2018).
Preoperative six-minute walk distance is associated with postoperative cognitive dysfunction.
Annals of Thoracic Surgery 106, 505-512.
94. Nishikimi M, Ogura T, Nishida K, Takahashi K, Fukaya K, Liu K, Nakamura M, Matsui S,
Matsuda N. (2018). Differential effect of mild therapeutic hypothermia depending on the findingsof hypoxic encephalopathy on early CT images in patients with post-cardiac arrest syndrome.
Resuscitation 128, 11-15.
95. Nishikimi M, Numaguchi A, Takahashi K, Miyagawa Y, Matsui K, Higashi M, Makishi G, Matsui
S, Matsuda N. (2018). Effect of administration of ramelteon, a melatonin receptor agonist, on the
duration of stay in the ICU: A single-center randomized placebo-controlled trial. Critical Care
Medicine 46, 1099-1105.
96. Kawai A, Goto T, Shibata T, Tani K, Mizutani S, Nishikawa A, Shibata T, Matsumoto S, Nagata
K, Narukawa M, Matsui S, Ando M, Toguchida J, Monden M, Heike T, Kimura S, Ueda R. (2018).
The current state of therapeutic development for rare cancers in Japan, and proposals for
improvement. Cancer Science 109, 1731-1737.
97. Sakai Y, Honda M, Matsui S, Komori O, Murayama T, Fujiwara T, Mizuno M, Imai Y, Yoshimura
K, Nasti A, Wada T, Iida N, Kitahara M, Horii R, Toshikatsu T, Nishikawa M, Okafuji H,
Mizukoshi E, Yamashita T, Yamashita T, Arai K, Kitamura K, Kawaguchi K, Takatori H,
Shimakami T, Terashima T, Hayashi T, Nio K, Kaneko S; Hokuriku Liver Study Group. (2019).
Development of novel diagnostic system for pancreatic cancer, including early stages, measuringmRNA of whole blood cells. Cancer Science 110, 1364-1388.
98. Nomura K, Hiyama TY, Sakuta H, Matsuda T, Lin CH, Kobayashi K, Kobayashi K, Kuwaki T,
Takahashi K, Matsui S, Noda M. (2019). [Na+] Increases in Body Fluids Sensed by Central Nax
Induce Sympathetically Mediated Blood Pressure Elevations via H+-Dependent Activation of
ASIC1a. Neuron 101, 60-75.e6.
99. Kasugai D, Nishikimi M, Nishida K, Higashi M, Yamamoto T, Numaguchi A, Takahashi K,

05APR2024

Matsui S, Matsuda N. (2019). Timing of administration of epinephrine predicts the responsivenessto epinephrine in norepinephrine-refractory septic shock: a retrospective study. Journal of
Intensive Care 7:20.
100.

Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Matsuda C, Nakamoto Y, Kotake

M, Kurachi K, Egawa T, Yasumasa K, Murata K, Ikawa O, Shinji S, Murotani K, Matsui S,
Teramukai S, Tomita N, Sugihara K; SACURA Study Group. (2019). Prospective Multicenter
Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer:
Results From the SACURA Trial. Journal of Clinical Oncology 37, 1886-1894.
101.

Nishikimi M, Ogura T, Nishida K, Takahashi K, Nakamura M, Matsui S, Matsuda N, Iwami

T. (2019). External validation of a risk classification at the emergency department of post-cardiac
arrest syndrome patients undergoing targeted temperature management. Resuscitation 140, 135141.
102.

Kasugai D, Hirakawa A, Ozaki M, Nishida K, Ikeda T, Takahashi K, Matsui S, Uenishi N.

(2019). Maximum norepinephrine dosage within 24 hours as an indicator of refractory septic
shock: a retrospective study. J Intensive Care Med. 35, 1285-1289.
103. Komori S, Ueno S, Ito Y, Sayo A, Meinert M, Kominami T, Inooka D, Kitagawa M, Nishida K,
Takahashi K, Matsui S, Terasaki H. (2019). Steeper macular curvature in eyes with non-highly
myopic retinitis pigmentosa. Invest Ophthalmol Vis Sci. 60, 3135-3141.
104. Yoshihara M, Kajiyama H, Tamauchi S, Suzuki S, Takahashi K, Matsui S, Kikkawa F. (2019).
Prognostic factors and effects of fertility-sparing surgery in women of reproductive age withovarian clear-cell carcinoma: a propensity score analysis. J Gynecol Oncol. 30, e102.
105. Yoshihara M, Kajiyama H, Tamauchi S, Iyoshi S, Yokoi A, Suzuki S, Kawai M, Nagasaka T,
Takahashi K, Matsui S, Kikkawa F. (2020). Prognostic impact of pelvic and para-aortic
lymphadenectomy on clinically-apparent stage I primary mucinous epithelial ovarian carcinoma:
a multi-institutional study with propensity score-weighted analysis. Jpn J Clin Oncol. 50(2): 145151.
106. Takagi H, Hagiwara D, Handa T, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Iwama S, Goto M,
Suga H, Banno R, Takahashi K, Matsui S, Arima H. (2020). Diagnosis of central diabetes
insipidus using a vasopressin radioimmunoassay during hypertonic saline infusion. Endocr J.
67(3): 267-274.
107. Fujii T, Shibata Y, Ban Y, Shitaokoshi A, Takahashi K, Matsui S, Nishiwaki K. (2020). A single
paravertebral injection via a needle vs. a catheter for the spreading to multiple intercostal levels:a randomized controlled trial. J Anesth. 34(1): 72-78.
108. Nakajima H, Nishikimi M, Shimizu M, Hayashi K, Inoue T, Nishida K, Takahashi K, Matsui S,
Nishida Y, Matsuda N. (2019). Clinical frailty scale score before ICU admission is associatedwith mobility disability in septic patients receiving early rehabilitation. Crit Care Explor. 1(12):05APR2024

e0066.
109. Yasuda Y, Nishikimi M, Nishida K, Takahashi K, Numaguchi A, Higashi M, Matsui S, Matsuda
N. (2020). Relationship between serum norepinephrine levels at ICU admission and the risk of
ICU-acquired delirium: secondary analysis of the melatonin evaluation of lowered inflammationof ICU trial. Crit Care Explor. 24; 2(2): e0082.
110. Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Matsui S, Teramukai S, Murotani K,
Ajioka Y, Shimazaki H, Maeda A, Takuma K, Yoshida T, Kambara T, Matsuda K, Takagane A,
Tomita N, Sugihara K; SACURA Study Group. (2020). Optimal criteria for G3 (poorly
differentiated) stage II colon cancer: prospective validation in a randomized controlled study(SACURA Trial). Am J Surg Pathol. 44(12), 1685-1698.
111. Nishida Y, Hamada S, Urakawa H, Ikuta K, Sakai T, Koike H, Ito K, Emoto R, Ando Y, Matsui
S. (2020). Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly
administration: A phase II clinical trial. Cancer Sci. 111(11), 4187-4194.
112. Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi
K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A,
Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki
N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. (2020). The PD-1 expression
balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade
therapies. Nat Immunol. 21(11), 1346-1358.
113. Okubo N, Matsui S, Matsumoto T, Sugimoto T, Hosoi T, Osakabe T, Watanabe K, Takami H,
Shiraki M, Nakamura T. (2020). Relationship between bone mineral density and risk of vertebral
fractures with denosumab treatment in Japanese postmenopausal women and men withosteoporosis. Calcif Tissue Int. 107(6), 559-566.
114. Yoshihara M, Kajiyama H, Tamauchi S, Iyoshi S, Yokoi A, Suzuki S, Kawai M, Nagasaka T,
Takahashi K, Matsui S, Kikkawa F. (2020). Impact of uterus-preserving surgery on Stage I
primary mucinous epithelial ovarian carcinoma: A multi-institutional study with propensity
score-weighted analysis. Int J Gynaecol Obstet. 150(2), 177-183
115. Omote N, Matsuda N, Hashimoto N, Nishida K, Sakamoto K, Ando A, Nakahara Y, Nishikimi
M, Higashi M, Matsui S, Hasegawa Y. (2020). High-flow nasal cannula therapy for acuterespiratory failure in patients with interstitial pneumonia: a retrospective observational study.
Nagoya J Med Sci. 82(2), 301-313.
116. Yasuda Y, Nishikimi M, Matsui K, Numaguchi A, Nishida K, Emoto R, Matsui S, Matsuda N.
(2021). The rCAST score is useful for estimating the neurological prognosis in pediatric patientswith post-cardiac arrest syndrome before ICU admission: External validation study using anationwide prospective registry. Resuscitation 168, 103-109.
117. Nishi T, Mutsuga M, Akita T, Narita Y, Fujimoto K, Tokuda Y, Nishida K, Matsui S, Nishiwaki

05APR2024

K, Usui A. (2021). Hypofibrinogenemia can be estimated by the predictive formula in aortic
surgery. Gen Thorac Cardiovasc Surg 69(10), 1376-1382.
118. Araki Y, Yokoyama K, Uda K, Kanamori F, Kurimoto M, Shiba Y, Mamiya T, Nishihori M, Izumi
T, Sumitomo M, Okamoto S, Matsui K, Emoto R, Wakabayashi T, Matsui S, Natsume A.
Postoperative stroke and neurological outcomes in the early phase after revascularization
surgeries for moyamoya disease: an age-stratified comparative analysis. Neurosurgical Review
44(5), 2785-2795.
119. Hiraiwa H, Kasugai D, Ozaki M, Goto Y, Jingushi N, Higashi M, Nishida K, Kondo T, Furusawa
K, Morimoto R, Okumura T, Matsuda N, Matsui S, Murohara T. (2021). Clinical impact ofvisually assessed right ventricular dysfunction in patients with septic shock. Sci Rep 11(1), 18823.
120. Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N, Iwami T. (2021).
Outcome Related to Level of Targeted Temperature Management in Postcardiac Arrest Syndromeof Low, Moderate, and High Severities: A Nationwide Multicenter Prospective Registry. Crit
Care Med 49(8), e741-e750.
121. Yoshihara M, Emoto R, Kitami K, Iyoshi S, Uno K, Mogi K, Tano S, Yoshikawa N, Matsui S,
Kajiyama H. (2021). A large-scale multi-institutional study evaluating prognostic aspects ofpositive ascites cytology and effects of therapeutic interventions in epithelial ovarian cancer. Sci
Rep 11(1), 15154.
122. Kasugai D, Ozaki M, Nishida K, Goto Y, Takahashi K, Matsui S, Matsuda N. (2021). Relative
platelet reductions provide better pathophysiologic signatures of coagulopathies in sepsis. Sci
Rep 11(1), 14033.
123. Hayashida K, Takegawa R, Nishikimi M, Aoki T, Emoto R, Shinozaki K, Miyara SJ, Rolston
DM, Li T, Shoaib M, Fukuda T, Molmenti EP, Suzuki M, Sasaki J, Matsui S, Becker LB. (2021).
The interplay between bystander cardiopulmonary resuscitation and ambient temperature on
neurological outcome after cardiac arrest: A nationwide observational cohort study. Resuscitation
164, 46-53.
124. Matsui S, Le-Rademacher J, Mandrekar SJ. (2021). Statistical models in clinical studies. J Thorac
Oncol 16(5), 734-739.
125. Nishikimi M, Nishida K, Shindo Y, Shoaib M, Kasugai D, Yasuda Y, Higashi M, Numaguchi A,
Yamamoto T, Matsui S, Matsuda N. (2021). Failure of non-invasive respiratory support after 6hours from initiation is associated with ICU mortality. PLoS One 16(4), e0251030.
126. Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Murotani K, Matsui S, Teramukai S,
Sugai T, Ajioka Y, Maruo H, Kotaka M, Tsujie M, Munemoto Y, Yamaguchi T, Kuroda H,
Fukunaga M, Tomita N, Sugihara K. (2021). Prognostic value of desmoplastic reaction
characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA
Trial). Br J Cancer 124(6), 1088-1097.

05APR2024

127. Yoshihara M, Tamauchi S, Iyoshi S, Kitami K, Uno K, Tano S, Matsui S, Kajiyama H. (2021).
Does complete-staging lymphadenectomy improve survival outcomes in stage I endometrioid
epithelial ovarian carcinoma? A multi-institutional retrospective study with propensity scoreweighted analysis. Jpn J Clin Oncol 51(3), 387-392.
128. Sakakibara T, Shindo Y, Kobayashi D, Sano M, Okumura J, Murakami Y, Takahashi K, Matsui
S, Yagi T, Saka H, Hasegawa Y. (2022). A prediction rule for severe adverse events in all
inpatients with community-acquired pneumonia: a multicenter observational study. BMC Pulm
Med. 22(1): 34.
129. Sano M, Shindo Y, Takahashi K, Okumura J, Sakakibara T, Murakami Y, Iguchi M, Yagi T, Matsui
S, Hasegawa Y. (2022). Risk factors for antibiotic resistance in hospital-acquired and ventilatorassociated pneumonia. J Infect Chemother. 28, 745-752.
130. Emoto R, Nishikimi M, Shoaib M, Hayashida K, Nishida K, Kikutani K, Ohshimo S, Matsui S,
Shime N, Iwami T. (2022). Prediction of prehospital change of the cardiac rhythm fromnonshockable to shockable in out-of-hospital patients with cardiac arrest: A post hoc analysis ofa nationwide, multicenter, prospective registry. J Am Heart Assoc. 11(12): e025048.
131. Teramoto T, Ogawa H, Ueshima H, Okada Y, Haze K, Matsui S, Fujikawa K, Hashimoto T, Sakui
S, Nishimura K, Kajita M, Horimoto A, Fernandez J. (2022). Effect of omega-3 fatty acids on
cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year postmarketing surveillance study (OCEAN3 survey). Expert Opin Drug Saf. 22(1), 81-90.
132. Matsuo S, Ushida T, Emoto R, Moriyama Y, Iitani Y, Nakamura N, Imai K, Nakano-Kobayashi
T, Yoshida S, Yamashita M, Matsui S, Kajiyama H, Kotani T. (2022). Machine learning prediction
models for postpartum depression: A multicenter study in Japan. J Obstet Gynaecol Res. 48,
1775-1785.
133. Iyoshi S, Sumi A, Yoshihara M, Kitami K, Mogi K, Uno K, Fujimoto H, Miyamoto E, Tano S,
Yoshikawa N, Emoto R, Matsui S, Kajiyama H. (2022). Obesity contributes to the stealthperitoneal dissemination of ovarian cancer: a multi-institutional retrospective cohort study.
Obesity 30, 1599-1607.
134. Nishida K, Usami T, Matsumoto N, Nishikimi M, Takahashi K, Matsui S. (2022). The finger-tonose test improved diagnosis of cerebrovascular events in patients presenting with isolateddizziness in the emergency department. Nagoya J Med Sci. 84, 621-629.
135. Murakami Y, Shindo Y, Sano M, Okumura J, Kobayashi H, Sakakibara T, Iguchi M, Takahashi
K, Yagi T, Matsui S, Hasegawa Y. (2022). Effects of lymphocyte and neutrophil counts and theirtime courses on mortality in patients with postoperative pneumonia. Sci Rep. 12(1):14564.
136. Okita M, Otani K, Gibo N, Matsui S. (2022). Systematic review and meta-analysis of celiac
plexus neurolysis for abdominal pain associated with unresectable pancreatic cancer. Pain Pract.
22, 652-661.

05APR2024

137. Yoshihara M, Mogi K, Kitami K, Uno K, Iyoshi S, Tano S, Fujimoto H, Miyamoto E, Yoshikawa
N, Emoto R, Matsui S, Kajiyama H. (2022). Who are the long-term survivors of recurrent ovariancarcinoma?: a retrospective analysis of a multicenter study. Int J Clin Oncol. 27, 1660-1668.
138. Kawai Y, Banno H, Sato T, Ikeda S, Tsuruoka T, Sugimoto M, Niimi K, Kodama A, Matsui K,
Matsui S, Komori K. (2022). Epicardial adipose tissue volume is associated with abdominal
aortic aneurysm expansion. J Vasc Surg. 76, 1253-1260.
139. Kobayashi H, Shindo Y, Kobayashi D, Sakakibara T, Murakami Y, Yagi M, Matsuura A, Sato K,
Matsui K, Emoto R, Yagi T, Saka H, Matsui S, Hasegawa Y; Central Japan Lung Study Group.
(2022). Extended-spectrum antibiotics for community-acquired pneumonia with a low risk for
drug-resistant pathogens. Int J Infect Dis. 124, 124-132.
140. Kato T, Iwano S, Hanamatsu Y, Nakaguro M, Emoto R, Okado S, Sato K, Noritake O, Nakanishi
K, Kadomatsu Y, Ueno H, Ozeki N, Nakamura S, Fukumoto K, Takeuchi T, Karube K, Matsui S,
Chen-Yoshikawa TF. (2023). Prognostic impact of highly solid component in early-stage solidlung adenocarcinoma. Quant Imaging Med Surg. 13(9): 5641-5652.
141. Miyamoto E, Suzuki H, Yoshihara M, Mogi K, Iyoshi S, Uno K, Fujimoto H, Kitami K, Tano S,
Emoto R, Matsui S, Kajiyama H. The prognostic impact of limited-staging surgery in patientswith stage IA epithelial ovarian cancer: a multi-center study with a propensity score-adjusted
analysis (2023). Jpn J Clin Oncol. 53(8): 698-703.
142. Tano S, Kotani T, Ushida T, Yoshihara M, Imai K, Nakamura N, Iitani Y, Moriyama Y, Emoto R,
Kato S, Yoshida S, Yamashita M, Kishigami Y, Oguchi H, Matsui S, Kajiyama H. (2023).
Evaluating glucose variability through OGTT in early pregnancy and its association withhypertensive disorders of pregnancy in non-diabetic pregnancies: a large-scale multi-center
retrospective study. Diabetol Metab Syndr. 15(1): 123.
143. Yagi M, Shindo Y, Mutoh Y, Sano M, Sakakibara T, Kobayashi H, Matsuura A, Emoto R, Matsui
S, Nakagawa T, Ogawa K. (2023). Factors associated with adverse drug reactions or death in very
elderly hospitalized patients with pulmonary tuberculosis. Sci Rep. 13(1): 6826.
144. Okita M, Otani K, Matsui S. (2023). Efficacy of endoscopic ultrasound-guided celiac plexus
neurolysis for abdominal pain in patients with unresectable pancreatic cancer: Network metaanalysis of randomized controlled trials. J Clin Gastroenterol. 57(10),1054-1062.
145. Teramoto T, Ogawa H, Ueshima H, Okada Y, Haze K, Matsui S, Fujikawa K, Hashimoto T, Sakui
S, Nishimura K, Kajita M, Horimoto A, Fernandez J. (2023). Effect of omega-3 fatty acids on
cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year postmarketing surveillance study (OCEAN3 survey). Expert Opin Drug Saf. 22(1), 81-90.
146. Okado S, Kato T, Hanamatsu Y, Emoto R, Imamura Y, Watanabe H, Kawasumi Y, Kadomatsu Y,
Ueno H, Nakamura S, Mizuno T, Takeuchi T, Matsui S, Chen-Yoshikawa TF. (2024). CHST4
gene as a potential predictor of clinical outcome in malignant pleural mesothelioma. Int J Mol

05APR2024

Sci. 25(4): 2270.
147. Kikutani K, Nishikimi M, Matsui K, Sakurai A, Hayashida K, Kitamura N, Tagami T, Nakada
TA, Matsui S, Ohshimo S, Shime N; SOS-KANTO 2017 Study Group. (2024). Prediction of theneurological outcomes post-cardiac arrest: A prospective validation of the CAST and rCAST. Am
J Emerg Med. 75: 46-52.
148. Okita M, Nakashima K, Yamamura T, Matsui S. (2024). Systematic review and meta-analysis of
the use of serum leucine-rich alpha-2 glycoprotein to assess Crohn's disease activity. Inflamm
Bowel Dis. (In press).